Report
EUR 14.00 For Business Accounts Only

Due to a more favourable environment, TERUMO slightly increases to Neutral

TERUMO (JP), a company active in the Medical Equipment industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 1 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date February 25, 2022, the closing price was JPY 3,661.00 and its target price was estimated at JPY 3,477.95.
Underlying
Terumo Corporation

Terumo is engaged in the manufacture and sale of medical products and equipment. Co.'s principal businesses are cardiac and vascular, general hospital, and blood management. Co.'s principal products are I.V. catheter, nelaton catheter, surgical tape, wound care dressing, syringe hypodermic needle, safety syringe and IV administration set; angiographic catheter, PTCA dilatation catheter, coronary stent, microcatheter and artificial vascular grafts; automated blood collection system, automated blood component processing device, blood bag system with leukocyte reduction filter, sterile tubing welder, pathogen reduction technology system, therapeutic apheresis system, and cell expansion system.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch